News Release

Gene interactions classify bowel tumors for personalized medicine

Researchers used gene interaction networks to group bowel cancers into six distinct clinical and molecular subtypes which could be used in personalized medicine

Peer-Reviewed Publication


This new taxonomy of bowel cancer will aid understanding of the disease and could ultimately be used by doctors for precision medicine – helping them to tailor the best treatments to individual patients. 

“Currently, disease staging is used to guide clinical management of people with bowel cancer, but this is inadequate because there can be substantial differences between tumours at a similar stage,” explains lead author Zaoqu Lu, Master at The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. “More detailed molecular classification of bowel cancer is more effective, but it is still based on a snapshot of the gene activity levels within a tumour at one point in time (for example, at a biopsy), and does not reflect the changing dynamics of gene activity and how genes interact with each other.”

By contrast, biological interaction networks – that is, maps of which genes commonly interact with each other – remain relatively stable irrespective of time and can more reliably characterise tissues. Moreover, gene interactions are highly conserved in normal tissue but extensively altered in disease. By quantifying an ‘interaction change’ for different gene pairs, it becomes possible to compare the overall change in gene interactions in diseased tissue, with that of the background level in normal tissue. 

The team applied this gene interaction network (GIN) approach using more than 2,000 bowel cancer tissue samples and 308 normal bowel tissue samples to construct a large-scale network of changes in gene interactions. Using the network, they were then able to group bowel cancers into six subtypes, each with different clinical and molecular features. The features included important tumour characteristics, such as the proportion of cancer cells to other cell types, and whether the cancer cells were similar to stem cells, which can influence how likely a tumour is to grow and spread. 

The GIN classification also identified groups with different immunogenicity – that is, how likely the bowel tumour tissue was to stimulate an immune response, which is crucial for determining whether patients might respond to immunotherapy. Other useful characteristics included likely prognosis, resistance to radiotherapy and immunotherapy treatments, and likelihood of sensitivity to different chemotherapy drugs – all of which can help tailor treatment. When the GIN approach was tested in 19 further bowel cancer datasets, the same six subtypes were consistently identified. 

The first GIN was based on more than 2,000 interactions between nearly 1,400 genes, and resulted in a classifier based on 289 genes. This would be impossible to test for in a clinical setting, so to provide a rapidly accessible clinical tool, the team reduced the classifier to a randomly selected 14-gene mini-classifier. When they used the mini-classifier on a subset of 214 bowel cancer samples they found it was as stable as the full classifier at identifying the six bowel cancer subtypes.

“Our study has identified and validated a high-resolution classification system which could serve as a tool for optimising treatment decisions for patients with bowel cancer,” says senior author Xinwei Han, Professor & Director of the Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. “The next step will be to confirm the biological and clinical interpretability of the six bowel cancer subtypes in a prospective clinical trial, but we believe that this new taxonomy could facilitate more effective personalised treatment of patients with bowel cancer.”


Media contacts

Emily Packer, Media Relations Manager


+44 (0)1223 855373

George Litchfield, Marketing and PR Assistant


About eLife

eLife transforms research communication to create a future where a diverse, global community of scientists and researchers produces open and trusted results for the benefit of all. Independent, not-for-profit and supported by funders, we improve the way science is practised and shared. From the research we publish, to the tools we build, to the people we work with, we’ve earned a reputation for quality, integrity and the flexibility to bring about real change. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at

To read the latest Cancer Biology research published in eLife, visit


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.